Fungal infections are rising due to global warming, with Candida auris emerging as a multidrug-resistant threat (30-40% mortality). New research from JNCASB and collaborators reveals that C. auris uses gene duplication (Erg11) and mutations (Fks1) to resist antifungals, and also exhibits the 'Eagle effect' where high drug doses paradoxically trigger compensatory chitin production, making the pathogen survive. This signals the end of the chemical arms race approach and calls for combination therapies and revised susceptibility testing limits.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Mortality: 30-40% for C. auris infections
- ›Azole Resistance: >90% clinical isolates resistant to fluconazole
- ›Target this Data: >90% Indian clinical isolates of C. auris are resistant to azole antifungals like fluconazole
- ›Target this Data: C. auris mortality rate = 30-40% in infected patients
- ›Target this Institution: PGIMER, Chandigarh holds a stock of 15,000 clinical fungal isolates
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.